John W. Walsh Alpha-1 Home Infusion Act of 2023
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
John W. Walsh Alpha-1 Home Infusion Act of 2023
This bill provides for Medicare coverage of treatment for alpha-1 antitrypsin (AAT) deficiency (a protein deficiency that raises the risk of lung and other diseases). Specifically, the bill provides for coverage of at-home augmentation therapy for beneficiaries with emphysema as a result of severe hereditary AAT deficiency. Treatment must be provided through qualified home infusion therapy suppliers; beneficiaries must be under the care of a physician, nurse practitioner, or physician assistant.
Referred to the Subcommittee on Health.
- Introduced in House Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). H.R. 4438: John W. Walsh Alpha-1 Home Infusion Act of 2023. 118th Congress. Open America. https://openamerica.io/bill/118-HR-4438/
"H.R. 4438: John W. Walsh Alpha-1 Home Infusion Act of 2023." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-HR-4438/.
H.R. 4438, 118th Cong. (2026), https://openamerica.io/bill/118-HR-4438/.
[H.R. 4438: John W. Walsh Alpha-1 Home Infusion Act of 2023](https://openamerica.io/bill/118-HR-4438/)